AlphaCentric Advisors’s Protagonist Therapeutics PTGX Stock Holding History

AlphaCentric Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.12M	Buy	9,171 +131	+1%	+$13.7K	0.95%	21
2026 Q1	$953K	Buy	9,040 +491	+6%	+$43.5K	0.95%	22
2025 Q4	$747K	Buy	+8,549	New	+$700K	0.74%	36
2024 Q4	$275K	Sell	7,123 -17,877	-72%	-$779K	0.27%	92
2024 Q3	$1.13M	Hold	25,000	–	–	0.84%	42
2024 Q2	$866K	Hold	25,000	–	–	0.64%	56
2024 Q1	$723K	Sell	25,000 -5,000	-17%	-$136K	0.44%	75
2023 Q4	$688K	Sell	30,000 -13,500	-31%	-$236K	0.46%	64
2023 Q3	$726K	Buy	+43,500	New	+$844K	0.41%	77

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

AlphaCentric Advisors's PTGX Position: Q2 2026 in Review

AlphaCentric Advisors increased its Protagonist Therapeutics (PTGX) stake by 1.4% in Q2 2026, buying an estimated $13.7K and bringing the position to 9,171 shares worth $1.12M. The position accounts for 0.95% of the portfolio, ranked #21.

AlphaCentric Advisors first reported a position in PTGX in Q3 2023 and has held it in 9 quarters since. The position peaked at $1.13M in Q3 2024. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

AlphaCentric Advisors held 9,171 shares of Protagonist Therapeutics worth $1.12M as of Q2 2026.
AlphaCentric Advisors bought 131 Protagonist Therapeutics shares in Q2 2026, an estimated $13.7K.
Protagonist Therapeutics made up 0.95% of AlphaCentric Advisors's portfolio in Q2 2026, its #21 holding.
AlphaCentric Advisors first reported a position in Protagonist Therapeutics in Q3 2023 and has held it in 9 quarters since.
AlphaCentric Advisors's Protagonist Therapeutics position peaked at $1.13M in Q3 2024.
344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.